BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors

Omar Hasan Ali, David Bomze, Sandra Ring, Fiamma Berner, Mirjam Fässler, Stefan Diem, Marie-Therese Abdou, Christoph Hammers, Shirin Emtenani, Anne Braun, Antonio Cozzio, Bernhard Mani, Wolfram Jochum, Enno Schmidt, Detlef Zillikens, Christian D Sadik, Lukas Flatz

Fingerprint

Dive into the research topics of 'BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors'. Together they form a unique fingerprint.

Medicine & Life Sciences